How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,088 results for

Depo Provera

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis

after the last study drug administration. Effective contraceptive methods include: Barrier methods such as condom, sponge or diaphragm combined with spermicide in foam, gel or cream; Hormonal contraception (oral, intramuscular, implant or transdermal) which include Depo Provera, Evra and Nuvaring; and Intrauterine device (IUD). Patients must be capable of giving informed consent and the consent must be obtained prior to any study related procedures. Exclusion criteria Patient with BSA > 15

2018 Clinical Trials

102. Effects of Seven Day Prucalopride Administration in Healthy Volunteers

Sufficiently fluent English to understand and complete the task Right handed Body Mass Index in the range of 18-30 Not currently taking any medications (except the contraceptive pill) Exclusion Criteria: Not fluent in English Any past or current Axis 1 DSM-V psychiatric disorder Current usage of psychoactive medication (except the contraceptive pill, the Depo-Provera injection or the progesterone implant) Current usage of any medication that will influence the MRI scan Current or past history of drug

2018 Clinical Trials

103. Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon

of such women. Adequate contraception is defined as vasectomy in male sexual partners of female participants, tubal ligation in women, or use of two contraceptive methods such as condoms and spermicide combination with an intrauterine device or Depo-Provera, or Norplant. Significant systemic or major illnesses other than liver disease, including, but not limited to, congestive heart failure, renal failure (eGFR <50 ml/min), organ transplantation, serious psychiatric disease or depression (only if felt

2018 Clinical Trials

104. Collection of Breath and Sweat to Identify Indicators of Hypoglycemia

and for the two weeks following the study. Acceptable contraception methods include: Oral contraceptive pill (OCP) Intrauterine Device (IUD, hormonal or copper) Male condoms Female condoms Diaphragm or cervical cap with spermicide Contraceptive patch (such as OrthoEvra) Contraceptive implant (such as Implanon, Nexplanon) Vaginal ring (such as NuvaRing) Progestin shot (such as Depo-Provera) Male partner with a vasectomy proven to be effective by semen analysis Abnormal EKG consistent with coronary artery

2018 Clinical Trials

105. Safety and Acceptability Study of a Non-Hormonal Ring

in male partner Sterility or known history of sperm dysfunction in male partner Within two calendar months from the last pregnancy outcome. Note: If recently pregnant must have had at least two spontaneous menses since pregnancy outcome. Current use of any hormonal contraceptive or a copper IUD, or use of Depo-Provera within the last 120 days Currently breastfeeding or having breastfed an infant in the last two months, or planning to breastfeed during the course of the study Significant gynecological

2018 Clinical Trials

106. A Study of AK111 in Healthy Subjects

) containing either copper or levonorgestrel (e.g. Mirena) Male sterilization (vasectomy) Female sterilization (e.g. by bilateral tubal ligation ('tying tubes') or hysterectomy) A method for which the failure rate is between 5% and 10% in real life use, in combination with a barrier method (male condom): Injectable contraceptive (e.g. Depo Provera) Oral Contraceptive Pill (combined hormonal pill or progestogen-only 'mini-pill') Vaginal contraceptive ring (e.g. NuvaRing) Please note that condoms alone

2018 Clinical Trials

107. Effects of Metformin During Nicotine Withdrawal

to enrollment. HIV-uninfected smokers: no diagnosis of HIV, either via blood test or self-report. Must not currently be interested in quitting smoking. Women of childbearing potential (based on medical history) must consent to use a medically accepted method of birth control (e.g., condoms and spermicide, oral contraceptive, Depo-Provera injection, contraceptive patch, tubal ligation) or abstain from sexual intercourse during the time they are in the study and using transdermal nicotine. If current or past

2018 Clinical Trials

108. Timed Aspirin Chronobiome

the 3 months prior to screening. Female subjects of child bearing potential must be using a medically acceptable method of contraception (oral contraception, Depo-Provera injection, IUD, condom with spermicide, diaphragm, cervical cap, progestin implant, abstinence, tubal ligation, oophorectomy, TAH) throughout the entire study period. All female subjects must consent to a serum and urine pregnancy test at screening and close-out and a urine pregnancy test just prior to the start of each treatment

2018 Clinical Trials

109. A Study to Evaluate the Efficacy of Salmon Protein Hydrolysate Powder on Energy Increase and Anti-inflammatory Modulation in Healthy Males and Females

, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Double-barrier method Intrauterine devices Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) Vasectomy of partner (shown successful as per appropriate follow-up) BMI of 18.5 kg/m²-32.5 kg/m² Agrees to comply with study procedures Willing to commit to taking product for 128 days

2018 Clinical Trials

110. Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg

is postpartum or post-abortal, she must have experienced a menstrual bleed since the pregnancy ended If a subject recently used non-injectable hormonal contraception, one bleeding episode consistent with menses must have occurred since last use; Willing to avoid use of any hormonal or intrauterine contraception until the end of the study; For women with a recent history of Depo Provera use, the most recent injection must have been at least 6 months before study entry, and the subject must have had at least

2018 Clinical Trials

111. VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

must agree to use adequate contraception (oral contraceptive pills, intrauterine device, Nexplanon, Depo-Provera, or permanent sterilization, etc., or another acceptable method as determined by the investigator) prior to study entry, for the duration of study participation, and 4 months after completion of VGX-3100 administration; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately

2018 Clinical Trials

112. Evaluation of Efficacy, Safety and Tolerability of VeraCept IUD

use of VeraCept; A previously inserted intrauterine device (IUD) that has not been removed by the time the study IUD is placed; History of previous IUD complications, such as perforation, expulsion, or pregnancy with IUD in place; Pain with current IUD; Injection of hormonal contraceptive (e.g., Depo-Provera) within the last 10 months (if injection greater than 3 months ago, must have had 2 normal menstrual cycles since the last injection); Planned use of any non-contraceptive estrogen

2018 Clinical Trials

113. Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of PVST. NODE-302

of signed informed consent until 30 days after the last administration of study drug. Females of childbearing potential should have a negative urine pregnancy test result at the Qualification Visit and at the Follow-up Visit(s), and must use an approved form of contraception between the 2 visits. Approved forms of contraception include hormonal intrauterine devices and hormonal contraceptives (oral birth control pills, Depo Provera®, patch, or other injectables) together with supplementary double

2018 Clinical Trials

114. G-Penâ„¢ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

and for 7 days after the last dose of study glucagon. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence. Breastfeeding: Nursing mothers will be allowed into the study. However, breast feeding during the during inpatient study visits and for 48 hours after each dose of study drug is not allowed. HbA1c >9.0% at Screening. BMI > 40 kg/m2

2018 Clinical Trials

115. Trial of Local Consolidation Therapy (LCT) After Osimertinib for Patients With EGFR Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC)

have a negative serum or urine pregnancy test; and (3) must agree to use adequate contraception for a minimum of two weeks prior to receiving study medication until 3 months after discontinuation of the study medication. NOTE: Acceptable methods of contraception include total and true sexual abstinence, hormonal contraceptives that are not prone to drug-drug interactions (IUS Levonorgestrel Intra Uterine System (Mirena), Medroxyprogesterone injections (Depo-Provera)), copper-banded intra-uterine

2018 Clinical Trials

116. Three Way Crossover Closed Loop Study With Xeris Glucagon

. Current use of a phone or other device so can be contacted by study staff off-campus. Willingness to follow all study procedures, including attending all clinic visits. Willingness to sign informed consent and HIPAA documents. Exclusion Criteria: Female of childbearing potential who is pregnant or intending to become pregnant or breast-feeding, or is not using adequate contraceptive methods. Acceptable contraception includes birth control pill/patch/vaginal ring, Depo-Provera, Norplant, an IUD

2018 Clinical Trials

117. Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections

contraception (e.g., oral contraceptives of estrogen and progestin combinations); depot injection (e.g., Depo-Provera); contraceptive implant (e.g., Norplant, Implanon); transdermally delivered contraceptive (e.g., Ortho Evra); intrauterine device; vaginal contraceptive ring (e.g.,NuvaRing); diaphragm plus spermicide; cervical cap; or male condom plus spermicide; partner vasectomy at least 6 months prior to baseline Vision and hearing (hearing aid permissible) sufficient for compliance with testing

2018 Clinical Trials

118. Evaluation of Physician-based Decision Support

of childbearing potential who is pregnant or intending to become pregnant or breast-feeding, or is not using adequate contraceptive methods. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence. Any cardiovascular disease, defined as a clinically significant EKG abnormality at the time of screening or any history of: stroke, heart failure

2018 Clinical Trials

119. Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

are: Total sexual abstinence (abstinence must be for the total duration of the trial and the follow-up period) Vasectomized sexual partner plus male condom (with participant assurance that partner received post-vasectomy confirmation of azoospermia) Tubal occlusion plus male condom Intra-uterine device - provided coils are copper-banded, plus male condom Intra-uterine system (IUS) levonorgestrel IUS (e.g., Mirena), plus male condom Medroxyprogesterone injections (Depo-Provera) plus male condom

2018 Clinical Trials

120. Safety and Immunogenicity of ChAd63 RH5 and MVA RH5 in Adults, Young Children and Infants Living in Tanzania

: Only participants who meet all the inclusion criteria will be enrolled into the trial; Group 1: Healthy male or female adults aged 18-35 years at the time of enrolment with signed consent. Group 1 (Female only participants): Must be non-pregnant (as demonstrated by a negative urine pregnancy test), and provide consent of their willingness to take Depo-Provera contraceptive during the study and safety follow-up period. Groups 2a & 2b: Healthy male or female young children aged 1-6 years at the time

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>